MORF240719P60000
- 1.50
- 0.000.00%
Morphic Newsroom
Morphic Holding Is Maintained at Hold by Stifel
Stifel Maintains Hold on Morphic Holding, Raises Price Target to $57
Morphic Holding Analyst Ratings
Stifel Maintains Morphic(MORF.US) With Hold Rating, Raises Target Price to $57
Stifel analyst Alex Thompson CFA maintains $Morphic(MORF.US)$ with a hold rating, and adjusts the target price from $30 to $57.According to TipRanks data, the analyst has a success rate of 51.6% and
Stifel Nicolaus Keeps Their Hold Rating on Morphic Holding (MORF)
Express News | Morphic Holding Inc : Stifel Raises Target Price to $57 From $30
Morphic Fund Continues Share Buy-Back
Morphic Ethical Fund Continues Share Buy-Back
Morphic Ethical Equities Continues Share Buy-Back
Morphic Ethical Equities Fund Underperforms Against MSCI ACWI Index in June
Morphic Ethical Fund Reports Latest Share Buy-Back
Jefferies Downgrades Morphic Holding to Hold From Buy, Price Target Is $57
Express News | Morphic Holding Inc : Jefferies Cuts Target Price to $57 From $60
Express News | Morphic Holding Inc : Jefferies Cuts to Hold From Buy
Eli Lilly LLY Acquires Morphic MORF; IDEAYA IDYA Phase 2 Data
Virpax VRPX +92% Litigation Settled; Morphic MORF +75% Acquired by Ely Lilly LLY
Jefferies Downgrades Morphic(MORF.US) to Hold Rating, Cuts Target Price to $57
Jefferies analyst Michael Yee downgrades $Morphic(MORF.US)$ to a hold rating, and adjusts the target price from $60 to $57.According to TipRanks data, the analyst has a success rate of 45.4% and a
Russell 2000 Index Notches Strongest Week Of Year, Hits 31-Month Highs: Outlook Is 'Clouded By Fed's Concerns Over Labor Market,' Analyst Warns
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Morphic Holding, Inc. Buyout